DRUG RECALL

Bone Marrow Stimulant Recalled

October 3, 2016

The US Food and Drug Administration (FDA) announced the recall of plerixafor injection (Mozobil) 24 mg/1.2 mL (NDC 0024-5862-01).

What prompted the Class III recall? The FDA noted that the company discovered incorrect and missing labeling on the products.

The recalled lot is #5RZ002, with an expiration of April 2018. More than 9,500 vials were impacted.

__________________________________________________________________________________________________________________________________________________________________________

RELATED CONTENT
Chemotherapy Agent Shortage Begins
Drug Shortage Prompts Temporary Importation

__________________________________________________________________________________________________________________________________________________________________________

The products were manufactured by Genzyme Corporation, which is a subsidiary of Sanofi.

In March, Genzyme recalled thyrotropin alfa for injection (Thyrogen) due to the presence of particulate matter.

 

--Stephanie Vaccaro

 

Reference:

US Food and Drug Administration. FDA Enforcement Report – Week of September 28, 2016. www.fda.gov. Accessed October 3, 2016.